Tags

Type your tag names separated by a space and hit enter

Chemerin levels in chronic kidney disease: A systematic review and meta-analysis.
Front Endocrinol (Lausanne). 2023; 14:1120774.FE

Abstract

INTRODUCTION

Chemerin as an inflammatory biomarker has gained attention in its biomarker capability. Several studies measured its levels in chronic kidney disease (CKD), as one of the common non-communicable causes of mortality and morbidity. Hence, this systematic review and meta-analysis aimed to investigate this association.

METHODS

PubMed, Scopus, Embase, and the Web of Science databases were systematically searched for studies investigating chemerin levels in any CKD stage (including end-stage renal disease patients undergoing hemodialysis (HD)) and comparing it with healthy controls. Random effect meta-analysis was performed to calculate the standardized mean difference (SMD) and 95% confidence interval (CI).

RESULTS

A total of eight studies were included, comprised of 875 individuals, with a mean age of 56.92 ± 11.78 years. All studies had high quality based on the New Castle-Ottawa Scale (NOS). Meta-analysis revealed significantly higher levels of chemerin in CKD patients compared to healthy controls (SMD 2.15, 95% CI 0.83-3.48, p-value<0.01). Additionally, HD patients had statistically higher levels of chemerin than controls (SMD 2.10, 95% CI 0.58-3.62, p-value=0.01). In meta-regression, publication year accounted for 23.50% and 24.17% of heterogeneity for these analyses, respectively.

CONCLUSION

Chemerin can be potentially used as a biomarker in CKD patients, which can suggest the inflammatory pathways for the disease. Further research is warranted for the assessment of its clinical applications and enlightening its role in the pathophysiology of CKD.

Links

PMC Free PDF

Authors+Show Affiliations

Behnoush AH
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Shobeiri P
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Bahiraie P
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amirkhani N
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Khalaji A
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Peiman S
Department of Internal Medicine, AdventHealth Orlando Hospital, Orlando, FL, United States.

MeSH

AgedHumansMiddle AgedBiomarkersKidney Failure, ChronicRenal DialysisRenal Insufficiency, ChronicChemokines

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

36761204

Citation

Behnoush, Amir Hossein, et al. "Chemerin Levels in Chronic Kidney Disease: a Systematic Review and Meta-analysis." Frontiers in Endocrinology, vol. 14, 2023, p. 1120774.
Behnoush AH, Shobeiri P, Bahiraie P, et al. Chemerin levels in chronic kidney disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1120774.
Behnoush, A. H., Shobeiri, P., Bahiraie, P., Amirkhani, N., Khalaji, A., & Peiman, S. (2023). Chemerin levels in chronic kidney disease: A systematic review and meta-analysis. Frontiers in Endocrinology, 14, 1120774. https://doi.org/10.3389/fendo.2023.1120774
Behnoush AH, et al. Chemerin Levels in Chronic Kidney Disease: a Systematic Review and Meta-analysis. Front Endocrinol (Lausanne). 2023;14:1120774. PubMed PMID: 36761204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chemerin levels in chronic kidney disease: A systematic review and meta-analysis. AU - Behnoush,Amir Hossein, AU - Shobeiri,Parnian, AU - Bahiraie,Pegah, AU - Amirkhani,Nikan, AU - Khalaji,Amirmohammad, AU - Peiman,Soheil, Y1 - 2023/01/25/ PY - 2022/12/10/received PY - 2023/1/11/accepted PY - 2023/2/10/entrez PY - 2023/2/11/pubmed PY - 2023/2/14/medline KW - chemerin KW - chronic kidney disease KW - meta-analysis KW - renal disease KW - systematic review SP - 1120774 EP - 1120774 JF - Frontiers in endocrinology JO - Front Endocrinol (Lausanne) VL - 14 N2 - INTRODUCTION: Chemerin as an inflammatory biomarker has gained attention in its biomarker capability. Several studies measured its levels in chronic kidney disease (CKD), as one of the common non-communicable causes of mortality and morbidity. Hence, this systematic review and meta-analysis aimed to investigate this association. METHODS: PubMed, Scopus, Embase, and the Web of Science databases were systematically searched for studies investigating chemerin levels in any CKD stage (including end-stage renal disease patients undergoing hemodialysis (HD)) and comparing it with healthy controls. Random effect meta-analysis was performed to calculate the standardized mean difference (SMD) and 95% confidence interval (CI). RESULTS: A total of eight studies were included, comprised of 875 individuals, with a mean age of 56.92 ± 11.78 years. All studies had high quality based on the New Castle-Ottawa Scale (NOS). Meta-analysis revealed significantly higher levels of chemerin in CKD patients compared to healthy controls (SMD 2.15, 95% CI 0.83-3.48, p-value<0.01). Additionally, HD patients had statistically higher levels of chemerin than controls (SMD 2.10, 95% CI 0.58-3.62, p-value=0.01). In meta-regression, publication year accounted for 23.50% and 24.17% of heterogeneity for these analyses, respectively. CONCLUSION: Chemerin can be potentially used as a biomarker in CKD patients, which can suggest the inflammatory pathways for the disease. Further research is warranted for the assessment of its clinical applications and enlightening its role in the pathophysiology of CKD. SN - 1664-2392 UR - https://www.unboundmedicine.com/medline/citation/36761204/Chemerin_levels_in_chronic_kidney_disease:_A_systematic_review_and_meta_analysis_ DB - PRIME DP - Unbound Medicine ER -